Connect Biopharma Holdings Limited CNTB
Set alert
At close · Oct 30
After hours · Oct 30, 6:56 PM ET
- YTD
- -71.55%
- 1 year
- -48.25%
- Open
- 0.827
- Prev close
- 0.8354
- Mkt cap
- 50.52M
- Vol
- 2.50M
- Avg vol
- 3.99M
- EPS
- -1.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7805
- High
- 0.8749
- Forward P/E
- -5.04
- Beta
- -0.31
- Short ratio
- 1.93
- Inst. own
- 44.43%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 30, 2023
- 50-d avg
- 1.12
- 200-d avg
- 1.34
- 1y target
- 7.00
News
-
4 days ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
1 week ago seekingalpha.com
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
1 week ago zacks.com
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…
1 week ago zacks.com
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate…
-
2 weeks ago benzinga.com
Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4
Leerink Partners analyst Will Soghikian assumes Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $4.
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
3 weeks ago defenseworld.net
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
4 weeks ago marketbeat.com
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease,…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…
1 month ago benzinga.com
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
1 month ago benzinga.com
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its global Phase 2 study.
1 month ago benzinga.com
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COPD treatment failure and high safety.
1 month ago seekingalpha.com
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday's regular session. Tenon Medical (NASDAQ:TNON) stock increased by 47.25% to $4.02. The market value of…
-
1 month ago benzinga.com
BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5
BTIG analyst Julian Harrison maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $10 to $5.
1 month ago benzinga.com
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday's pre-market session. Connect Biopharma Hldgs (NASDAQ:CNTB) stock increased by 79.43% to $1.78. The…
-
1 month ago benzinga.com
Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85%
Key topline results include:Rademikibart significantly reduced the rate of treatment failure by 81% through Week 4 compared to placebo (p=0.0122)Rademikibart significantly reduced the rate of new…
1 month ago globenewswire.com
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
-
1 month ago benzinga.com
Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5
Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $8 to $5.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
-
1 month ago benzinga.com
Canaccord Genuity Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $6
Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $7 to $6.
1 month ago seekingalpha.com
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…
-
1 month ago benzinga.com
BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target
BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $10 price target.
1 month ago benzinga.com
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart.
1 month ago benzinga.com
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Connect Biopharma asthma drug rademikibart misses primary endpoint but shows improved lung function and a favorable safety profile.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1…
-
1 month ago benzinga.com
Connect Biopharma's Interim Topline Data from Phase 2 Study Shows Rademikibart Reduced Treatment Failure Rate at 28 Days by 66% and Improved Lung Function Vs. Placebo
Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory…
1 month ago globenewswire.com
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to placebo – –Rademikibart produced a rapid, statistically significant improvement in lung function at Day…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The…
1 month ago globenewswire.com
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's after-market session. The company's market cap stands at $5.1 million. Picard Medical (AMEX:PMI) stock…
2 months ago globenewswire.com
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – –…
2 months ago defenseworld.net
Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm,…
3 months ago seekingalpha.com
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent
CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and…
-
3 months ago benzinga.com
Oppenheimer Initiates Coverage On Connect Biopharma Hldgs with Outperform Rating, Announces Price Target of $8
Oppenheimer analyst Mazahir Alimohamed initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $8.
-
4 months ago benzinga.com
Piper Sandler Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight rating and announces Price Target of $7.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
-
4 months ago benzinga.com
Connect Biopharma Completes Enrollment In Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart As Adjunct To Standard Of Care For Acute Exacerbations In Asthma And Type 2 Inflammation
– On track to also complete enrollment in the Seabreeze STAT COPD study this month –– Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 –– Strong balance sheet…
4 months ago globenewswire.com
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
5 months ago benzinga.com
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.
-
5 months ago benzinga.com
Canaccord Genuity Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $6
Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $6.
5 months ago marketbeat.com
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits…
-
5 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Overweight rating and announces Price Target of $4.
5 months ago globenewswire.com
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on…
-
5 months ago benzinga.com
Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.43 percent. This is a 78.95 percent decrease over…